Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 09:15 ET | Source: GRI Bio, Inc.

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently ...
April 01, 2025 11:15 ET | Source: GRI Bio, Inc.

GRI Bio Announces Pricing of $5.0 Million Public Offering

LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
February 19, 2025 09:00 ET | Source: GRI Bio, Inc.

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
July 01, 2024 08:45 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the 8th Annual IPF Summit

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
June 28, 2024 16:05 ET | Source: GRI Bio, Inc.

GRI Bio Announces Closing of $4.0 Million Public Offering

LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
January 26, 2024 08:05 ET | Source: GRI Bio, Inc.

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
November 15, 2023 08:05 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
June 13, 2023 08:35 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
April 27, 2023 09:05 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event

- Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or...